A review of ramelteon in the treatment of sleep disorders

Research output: Contribution to journalArticle

Abstract

Ramelteon is a selective melatonin receptor (MT1 and MT2) agonist that has been approved by the US Food and Drug Administration for the treatment of insomnia characterized by difficulty with sleep onset. It is the only approved steep-promoting medication that does not have a direct sedating effect, but rather enhances sleep through effects on sleep regulatory mechanisms within the suprachiasmatic nucleus. Ramelteon has been shown to have no abuse liability and therefore is not scheduled by the U.S. Drug Enforcement Agency as a controlled substance. It is available as an 8 mg tablet, which should be taken approximately 30 minutes prior to bedtime. The FDA approval contains no limitation on how long the medication may be prescribed.

Original languageEnglish (US)
Pages (from-to)69-79
Number of pages11
JournalNeuropsychiatric Disease and Treatment
Volume4
Issue number1 A
StatePublished - 2008

Fingerprint

Sleep
Melatonin MT1 Receptor
Melatonin MT2 Receptor
Controlled Substances
Suprachiasmatic Nucleus
Sleep Initiation and Maintenance Disorders
United States Food and Drug Administration
Tablets
Therapeutics
Pharmaceutical Preparations
Sleep Wake Disorders
ramelteon

Keywords

  • Circadian rhythm
  • Insomnia
  • Melatonin receptors
  • Ramelteon
  • Sleep-wake cycle

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

A review of ramelteon in the treatment of sleep disorders. / Neubauer, David.

In: Neuropsychiatric Disease and Treatment, Vol. 4, No. 1 A, 2008, p. 69-79.

Research output: Contribution to journalArticle

@article{3bfbc9305fcd404f8607a0ae841a81e6,
title = "A review of ramelteon in the treatment of sleep disorders",
abstract = "Ramelteon is a selective melatonin receptor (MT1 and MT2) agonist that has been approved by the US Food and Drug Administration for the treatment of insomnia characterized by difficulty with sleep onset. It is the only approved steep-promoting medication that does not have a direct sedating effect, but rather enhances sleep through effects on sleep regulatory mechanisms within the suprachiasmatic nucleus. Ramelteon has been shown to have no abuse liability and therefore is not scheduled by the U.S. Drug Enforcement Agency as a controlled substance. It is available as an 8 mg tablet, which should be taken approximately 30 minutes prior to bedtime. The FDA approval contains no limitation on how long the medication may be prescribed.",
keywords = "Circadian rhythm, Insomnia, Melatonin receptors, Ramelteon, Sleep-wake cycle",
author = "David Neubauer",
year = "2008",
language = "English (US)",
volume = "4",
pages = "69--79",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",
number = "1 A",

}

TY - JOUR

T1 - A review of ramelteon in the treatment of sleep disorders

AU - Neubauer, David

PY - 2008

Y1 - 2008

N2 - Ramelteon is a selective melatonin receptor (MT1 and MT2) agonist that has been approved by the US Food and Drug Administration for the treatment of insomnia characterized by difficulty with sleep onset. It is the only approved steep-promoting medication that does not have a direct sedating effect, but rather enhances sleep through effects on sleep regulatory mechanisms within the suprachiasmatic nucleus. Ramelteon has been shown to have no abuse liability and therefore is not scheduled by the U.S. Drug Enforcement Agency as a controlled substance. It is available as an 8 mg tablet, which should be taken approximately 30 minutes prior to bedtime. The FDA approval contains no limitation on how long the medication may be prescribed.

AB - Ramelteon is a selective melatonin receptor (MT1 and MT2) agonist that has been approved by the US Food and Drug Administration for the treatment of insomnia characterized by difficulty with sleep onset. It is the only approved steep-promoting medication that does not have a direct sedating effect, but rather enhances sleep through effects on sleep regulatory mechanisms within the suprachiasmatic nucleus. Ramelteon has been shown to have no abuse liability and therefore is not scheduled by the U.S. Drug Enforcement Agency as a controlled substance. It is available as an 8 mg tablet, which should be taken approximately 30 minutes prior to bedtime. The FDA approval contains no limitation on how long the medication may be prescribed.

KW - Circadian rhythm

KW - Insomnia

KW - Melatonin receptors

KW - Ramelteon

KW - Sleep-wake cycle

UR - http://www.scopus.com/inward/record.url?scp=41549115007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549115007&partnerID=8YFLogxK

M3 - Article

C2 - 18728808

AN - SCOPUS:41549115007

VL - 4

SP - 69

EP - 79

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

IS - 1 A

ER -